The 36-month beta value for TOI is at 0.49. Analysts have varying views on the stock, with 0 analysts rating it as a “buy,” 1 rating it as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for TOI is 36.80M, and currently, shorts hold a 0.67% of that float. The average trading volume for TOI on November 22, 2024 was 714.12K shares.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
TOI) stock’s latest price update
Oncology Institute Inc (NASDAQ: TOI)’s stock price has plunge by -0.42relation to previous closing price of 0.16. Nevertheless, the company has seen a -14.25% plunge in its stock price over the last five trading sessions. globenewswire.com reported 2024-11-21 that Proof that Digital Transformation and Smarter Supply Chains Can Massively Cut Costs Proof that Digital Transformation and Smarter Supply Chains Can Massively Cut Costs
TOI’s Market Performance
Oncology Institute Inc (TOI) has seen a -14.25% fall in stock performance for the week, with a -52.94% decline in the past month and a -57.13% plunge in the past quarter. The volatility ratio for the week is 29.76%, and the volatility levels for the past 30 days are at 17.29% for TOI. The simple moving average for the past 20 days is -37.97% for TOI’s stock, with a -79.54% simple moving average for the past 200 days.
Analysts’ Opinion of TOI
Many brokerage firms have already submitted their reports for TOI stocks, with Jefferies repeating the rating for TOI by listing it as a “Buy.” The predicted price for TOI in the upcoming period, according to Jefferies is $2.50 based on the research report published on February 26, 2024 of the current year 2024.
Guggenheim, on the other hand, stated in their research note that they expect to see TOI reach a price target of $7. The rating they have provided for TOI stocks is “Buy” according to the report published on September 14th, 2022.
Jefferies gave a rating of “Buy” to TOI, setting the target price at $10 in the report published on August 15th of the previous year.
TOI Trading at -46.87% from the 50-Day Moving Average
After a stumble in the market that brought TOI to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -93.83% of loss for the given period.
Volatility was left at 17.29%, however, over the last 30 days, the volatility rate increased by 29.76%, as shares sank -53.03% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -53.58% lower at present.
During the last 5 trading sessions, TOI fell by -15.11%, which changed the moving average for the period of 200-days by -92.24% in comparison to the 20-day moving average, which settled at $0.2487. In addition, Oncology Institute Inc saw -92.43% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at TOI starting from Havencrest Healthcare Partners, who sale 8,637 shares at the price of $2.12 back on Jan 29 ’24. After this action, Havencrest Healthcare Partners now owns 0 shares of Oncology Institute Inc, valued at $18,310 using the latest closing price.
Havencrest Healthcare Partners, the 10% Owner of Oncology Institute Inc, sale 24,915 shares at $2.30 during a trade that took place back on Jan 24 ’24, which means that Havencrest Healthcare Partners is holding 27,498 shares at $57,304 based on the most recent closing price.
Stock Fundamentals for TOI
Current profitability levels for the company are sitting at:
- -0.17 for the present operating margin
- 0.13 for the gross margin
The net margin for Oncology Institute Inc stands at -0.17. The total capital return value is set at -0.48. Equity return is now at value -131.66, with -28.92 for asset returns.
Based on Oncology Institute Inc (TOI), the company’s capital structure generated 0.86 points at debt to capital in total, while cash flow to debt ratio is standing at -0.35. The debt to equity ratio resting at 6.35. The interest coverage ratio of the stock is -7.68.
Currently, EBITDA for the company is -70.45 million with net debt to EBITDA at -1.19. When we switch over and look at the enterprise to sales, we see a ratio of 0.23. The receivables turnover for the company is 6.91for trailing twelve months and the total asset turnover is 2.11. The liquidity ratio also appears to be rather interesting for investors as it stands at 2.49.
Conclusion
In conclusion, Oncology Institute Inc (TOI) has had a bad performance lately. Opinion on the stock among analysts is mixed, with some giving it a “buy” rating and others a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
